Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Names Dr. Stewart Lonky to Board of Directors
November 15, 2004

Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced the appointment of Stewart Lonky, MD, FACP, MBA to its Board of Directors.

Dr. Stewart Lonky attended St. Lawrence University in Canton, New York, where he received his bachelor's degree in chemistry, and then went on to earn his medical degree at the State University of New York, Downstate Medical Center in 1971. Dr. Lonky has been a practicing physician in the Los Angeles Area since 1982. He is Board Certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. Prior to entering practice, Dr. Lonky served as a full-time faculty member at the University of California, San Diego in the Department of Medicine, Pulmonary Division, where he was engaged in research in the biochemistry of lung injury. He was a National Institutes of Health (NIH) Postdoctoral Fellow from 1974-77. He published over twenty articles and abstracts in the peer-reviewed literature during that time, and authored two book chapters.

Dr. Lonky founded the Trylon Corporation with his brothers in 1985, and has served as the Chief Medical Officer of that company since 1990. This company has developed diagnostic products for the early diagnosis of cervical and oral cancer, and Dr. Lonky's responsibilities have included product development, the direction of clinical research and interacting with regulatory agencies, including the U.S. Food and Drug Administration (FDA). In these roles he has been instrumental in successfully bringing a number of products to the medical marketplace. He has continued to be engaged in both clinical and biochemical research, and has published research articles in the peer-reviewed literature in the areas of cervical cancer and cellular pathophysiology. Since the company's products are cleared for marketing in a number of foreign countries, Dr. Lonky has experience in clinical research and regulatory affairs abroad.

Dr. Lonky earned his Masters in Business Administration (MBA) from Pepperdine University in 1993, and has lectured at Pepperdine in the executive MBA program in the past. He has also served on the Corporate Advisory Board of a National Nurse Practitioner's Association and served on the Medical Advisory Board of an international nutrition company. Dr. Lonky continues to make his home in Southern California.

"Working with a company like Nutra Pharma is exciting for me, because it is on the threshold of making important contributions to medicine in a very practical way," commented Dr. Stewart Lonky. "The company's target areas of research are in clinically important areas that affect large numbers of people in many countries. That alone is a reason for me to want to team up with Nutra Pharma. When you add to that the innovative approaches of the technologies we are working with, you have a prescription for success," he added.

"Dr. Lonky's background in the medical device arena and his understanding of the FDA regulatory environment will prove to be invaluable resources to Nutra Pharma," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "I'm very excited to be working with Dr. Lonky. He adds necessary experience to the Board that will allow Nutra Pharma to move from its development stage into the marketplace to accomplish our goals of near-term revenues," he concluded.

Commenting on how he envisions his contribution to the Company, Dr. Lonky stated, "I believe that the skills I have developed over the past 20 years at Trylon will mesh seamlessly with the needs of Nutra Pharma at this stage of its development. I am looking forward to rolling up my sleeves and helping to move our technologies to the market."

Dr. Lonky serves on the Board of Directors of Nutra Pharma effective November 11, 2004.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Naming Dr. Stewart Lonky to the Nutra Pharma Board of Directors should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics